Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV - Hepatitis C virus coinfected patients

Journal of Infectious Diseases

Volumn 203, Issue 12, 2011, Pages 1802-1806

  Reiberger, T ^a   Payer, B A ^a   Kosi, L ^a   Heil, P M ^a   Rieger, A ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ADULT; ARTICLE; BODY MASS; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONCURRENT INFECTION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 79957534092     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir194     Document Type: Article

References (15)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6-9.
2. Rosenthal E, Pialoux G, Bernard N, et al. GERMIVIC Joint Study Group. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007; 14:183-8.
3. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-89.
4. Carrat F, Bani-Sadr F, Pol S, et al. ANRS HCO2 RIBVAC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004; 292:2839-48.
5. Chung RT, Andersen J, Volberding P, et al. AIDS Clinical Trials Group A5071 Study Team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9. (Pubitemid 38988594)
6. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-36.
7. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-512. (Pubitemid 30257347)
8. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002; 123:1070-83.
9. Aberle JH, Formann E, Steindl-Munda P, et al. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol 2006; 36:24-31. (Pubitemid 44360574)
10. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
11. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
12. Hammer SM, Eron JJ Jr., Reiss P, et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-70.
13. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
14. Soriano V, Bravo R, Samaniego JG, et al. CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. HIV-Hepatitis Spanish Study Group. AIDS 1994; 8: 1621-2. (Pubitemid 24335102)
15. + T-cell counts. J Acquir Immune Defic Syndr 2009; 52:452-8.